Loading...

PKI - PerkinElmer, Inc.

Analyst Coverage Initiated Signal for 05-18-2022
Analyst Coverage Initiated: PKI rating Underweight by Barclays
Price Target: $125



Stock Signal Information


Signal

Analyst Coverage Initiated Stock
Report Date: 05-18-2022
Symbol: PKI - PerkinElmer, Inc.
Sector: Healthcare
Industry: Diagnostics & Research
Analyst Coverage Initiated: PKI rating Underweight by Barclays
Price Target: $125

  PKI Technical Chart

Company Contact

PerkinElmer, Inc. (PKI)
940 Winter St
Boston, MASSACHUSETTS 02451
Phone: 17816635776
Website: https://www.perkinelmer.com
CEO: Mr. Prahlad Singh


Company Profile

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophym, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.